BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27718274)

  • 1. The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome.
    Leach DA; Trotta AP; Need EF; Risbridger GP; Taylor RA; Buchanan G
    Prostate; 2017 Feb; 77(2):185-195. PubMed ID: 27718274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.
    Periyasamy S; Warrier M; Tillekeratne MP; Shou W; Sanchez ER
    Endocrinology; 2007 Oct; 148(10):4716-26. PubMed ID: 17615153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.
    Leach DA; Need EF; Toivanen R; Trotta AP; Palethorpe HM; Tamblyn DJ; Kopsaftis T; England GM; Smith E; Drew PA; Pinnock CB; Lee P; Holst J; Risbridger GP; Chopra S; DeFranco DB; Taylor RA; Buchanan G
    Oncotarget; 2015 Jun; 6(18):16135-50. PubMed ID: 25965833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A.
    Periyasamy S; Hinds T; Shemshedini L; Shou W; Sanchez ER
    Oncogene; 2010 Mar; 29(11):1691-701. PubMed ID: 20023700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.
    Ni L; Yang CS; Gioeli D; Frierson H; Toft DO; Paschal BM
    Mol Cell Biol; 2010 Mar; 30(5):1243-53. PubMed ID: 20048054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer.
    Febbo PG; Lowenberg M; Thorner AR; Brown M; Loda M; Golub TR
    J Urol; 2005 May; 173(5):1772-7. PubMed ID: 15821585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
    Wikström P; Marusic J; Stattin P; Bergh A
    Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer.
    Cano P; Godoy A; Escamilla R; Dhir R; Onate SA
    Cancer Res; 2007 Jan; 67(2):511-9. PubMed ID: 17234758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.
    Ricciardelli C; Choong CS; Buchanan G; Vivekanandan S; Neufing P; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
    Prostate; 2005 Apr; 63(1):19-28. PubMed ID: 15378523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.
    Henshall SM; Quinn DI; Lee CS; Head DR; Golovsky D; Brenner PC; Delprado W; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2001 Jan; 61(2):423-7. PubMed ID: 11212224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FKBP51 and FKBP52 regulate androgen receptor dimerization and proliferation in prostate cancer cells.
    Maeda K; Habara M; Kawaguchi M; Matsumoto H; Hanaki S; Masaki T; Sato Y; Matsuyama H; Kunieda K; Nakagawa H; Shimada M
    Mol Oncol; 2022 Feb; 16(4):940-956. PubMed ID: 34057812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells.
    Liao CP; Chen LY; Luethy A; Kim Y; Kani K; MacLeod AR; Gross ME
    Endocr Relat Cancer; 2017 Apr; 24(4):157-170. PubMed ID: 28264911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor beta 1 and androgen receptors in prostate neoplasia.
    Cardillo MR; Petrangeli E; Salvatori L; Ravenna L; Di Silverio F
    Anal Quant Cytol Histol; 2000 Oct; 22(5):403-10. PubMed ID: 11064817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion.
    Li Y; Li CX; Ye H; Chen F; Melamed J; Peng Y; Liu J; Wang Z; Tsou HC; Wei J; Walden P; Garabedian MJ; Lee P
    J Cell Mol Med; 2008 Dec; 12(6B):2790-8. PubMed ID: 18266956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asporin is a stromally expressed marker associated with prostate cancer progression.
    Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
    Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FKBP51 Immunohistochemical Expression: A New Prognostic Biomarker for OSCC?
    Russo D; Merolla F; Mascolo M; Ilardi G; Romano S; Varricchio S; Napolitano V; Celetti A; Postiglione L; Di Lorenzo PP; Califano L; Dell'Aversana GO; Astarita F; Romano MF; Staibano S
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells.
    Koochekpour S; Lee TJ; Sun Y; Hu S; Grabowski GA; Liu Z; Garay J
    J Cell Biochem; 2008 Aug; 104(6):2272-85. PubMed ID: 18481277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression.
    Zhao H; Coram MA; Nolley R; Reese SW; Young SR; Peehl DM
    J Urol; 2012 Dec; 188(6):2158-64. PubMed ID: 23088973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role for the androgen-receptor in clinically localized and advanced prostate cancer.
    Mohler JL
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):357-72. PubMed ID: 18471792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.